Trial intelligence / Profile preview

Bemotrizinol PK in topical maximum usage trial

NCT05277376Phase 3Completed

Sponsor
DSM-Firmenich
Start
Mar 2022
Primary completion
Oct 2022
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of bemcentinib in sunburn, sponsored by DSM-Firmenich. Started Mar 2022; status: completed.

02

Drugs

bemcentinib
03

Conditions

sunburn

Beyond the preview

Go deeper on NCT05277376.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05277376.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call